Showing 2951-2960 of 3572 results for "".
- IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosaceahttps://practicaldermatology.com/news/irb-approval-means-biopharmx-to-move-ahead-on-phase-2-trial-of-bpx-04-for-rosacea/2457665/BioPharmX Corporation has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. Based on data from its open-label feasibility study which assessed tolera
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o
- Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammationhttps://practicaldermatology.com/news/experimental-drug-may-reverse-hair-loss-hair-whitening-and-skin-inflammation/2457669/An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins study in mice. The investigators say the compound halts the production of glycosphingolipi
- Catch a Sneak Peek of Ground Up Season 2 at Summer AADhttps://practicaldermatology.com/news/get-a-sneak-peek-of-ground-up-season-2-at-summer-aad/2457671/The publishers of Practical Dermatology® and Modern Aesthetics® magazines are offering a sneak peek of the coming new season of the acclaimed video series, Ground Up, at Summer AAD in Chicago. Ground Up Season 1 took viewers
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- Cutera's New truSculpt iD Offers Personalized Body Sculptinghttps://practicaldermatology.com/news/cuteras-new-trusculpt-id-offers-personalized-body-sculpting/2457693/Cutera, Inc's new truSculpt® iD offers an evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes. truSculpt iD offers physicians and other qualified practitioners the flexibility to deliver personalized body sculpti
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut